• Shin-Young Na, Eva Mracsko, Joanne van Ryn, and Roland Veltkamp.
• Department of Neurology, University of Heidelberg, Heidelberg, Germany.
• Ann. Neurol. 2015 Jul 1; 78 (1): 137-41.

AbstractLack of specific antidotes is a major concern in intracerebral hemorrhage (ICH) related to direct anticoagulants including dabigatran (OAC-ICH). We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH. Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab. Pretreatment with DE increased intracerebral hematoma volume and cerebral hemoglobin content. Idarucizumab in equimolar dose prevented excess hematoma expansion for both DE doses. In more extensive ICH, idarucizumab significantly reduced mortality. Thus, idarucizumab prevents excess intracerebral hematoma formation in mice anticoagulated with dabigatran and reduces mortality.© 2015 American Neurological Association.

32 keywords...

hide…